Gilead Sciences (GILD) : Domini Social Investments reduced its stake in Gilead Sciences by 10.52% during the most recent quarter end. The investment management company now holds a total of 6,245 shares of Gilead Sciences which is valued at $516,462 after selling 734 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on May 12, 2016.Gilead Sciences makes up approximately 14.08% of Domini Social Investments’s portfolio.
Other Hedge Funds, Including , Cibc World Markets Corp reduced its stake in GILD by selling 310,664 shares or 20.37% in the most recent quarter. The Hedge Fund company now holds 1,214,718 shares of GILD which is valued at $100.5 Million. Gilead Sciences makes up approx 3.36% of Cibc World Markets Corp’s portfolio.Tdam Usa boosted its stake in GILD in the latest quarter, The investment management firm added 24,067 additional shares and now holds a total of 167,262 shares of Gilead Sciences which is valued at $14.2 Million. Gilead Sciences makes up approx 0.69% of Tdam Usa’s portfolio.United Asset Strategies boosted its stake in GILD in the latest quarter, The investment management firm added 2,403 additional shares and now holds a total of 61,365 shares of Gilead Sciences which is valued at $5.2 Million. Gilead Sciences makes up approx 2.26% of United Asset Strategies’s portfolio.Jennison Associates reduced its stake in GILD by selling 210,534 shares or 95.84% in the most recent quarter. The Hedge Fund company now holds 9,147 shares of GILD which is valued at $774,568.
Gilead Sciences opened for trading at $82.17 and hit $83.08 on the upside on Friday, eventually ending the session at $82.64, with a gain of 0.61% or 0.5 points. The heightened volatility saw the trading volume jump to 79,52,983 shares. Company has a market cap of $110,061,770 M.
On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.
Investors should note that on Apr 28, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Jun 14, 2016 as the ex-dividend date and fixed the record date on Jun 16, 2016. The payable date has been fixed on Jun 29, 2016.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.